SK Bio-Pharmaceuticals Enters into a Licensing Agreement with Premier Chinese Biopharmaceutical Company
SEOUL, Korea--(BUSINESS WIRE)--South Korean biotech SK biopharmaceuticals announced yesterday that they entered into a research and development agreement with Medicilon, of Shanghai, China, for their novel new small molecule SKL-PSY that is being developed for the treatment of depression and bipolar disorder.